About Commercialization at UHN
Enabling and leading commercialization and industry partnership for a healthier world, we are the research commercialization hub located at Toronto’s University Health Network (UHN). UHN is Canada’s largest research hospital, consisting of seven research institutes located within the hospital system comprised of Princess Margaret Cancer Centre, Toronto General, Toronto Rehabilitation, and Toronto Western hospitals, all affiliated with the University of Toronto and is the largest driver of medical research and innovation in the greater Toronto region.
As the leading research commercialization institution in Canada, and within the top 10 research commercialization hospitals in North America (Source: AUTM Licensing Survey), we are UHN’s catalyst for accelerating the world-class research and innovation at UHN into medical products, devices and therapies that improve care for patients around the world. This is how we create a healthier world.
Technologies discovered and developed at UHN have already formed the basis for many global products and services including pharmaceuticals, biologics, devices, and diagnostics, and represent the foundation for UHN spin-out companies.
The basic research initiatives and translational expertise of UHN’s research and clinical investigators continue to generate a large and growing portfolio of opportunities for corporate partnerships and alliances, and our seasoned team of business professionals shepherds the world-class science and discovery living at UHN toward maximum patient impact: medical products, devices, and therapies that change lives globally.
Together with the world-class UHN research community, our work delivers on our recently-launched Commercialization Lives Here strategy, elevating Canada as a world destination for life science commercialization.
Our start-up model
UHN has a unique technology incubation model that provides in-house funding to help early-stage technologies advance, making them ready to commercialize. This in-house technology de-risking approach is delivered with support from the Princess Margaret Cancer Foundation via the Princess Margaret Cancer Centre Innovation Acceleration Fund (IAF) and has allowed our start-ups to gain the confidence of major investment partners. Coupled with this approach, UHN seeks experienced management teams to lead its start-ups, setting them up for long-term success.
We compete with the biggest names in the US and at home; our lineup of start-ups includes BlueRock Therapeutics, Trillium Therapeutics, Adela Bio Inc., Treadwell Therapeutics, and AvroBio amongst others, boasting more than $5 billion injected into the economy.
- For more information: https://uhncommercialization.ca/
- Commercialization Lives Here strategy: https://uhncommercialization.ca/our-strategy
- Our success story: https://www.youtube.com/channel/UCYMSkVYMEJlLGAikS-qhhFw